DC Field | Value | Language |
---|---|---|
dc.contributor.author | In Pyo Choi | - |
dc.contributor.author | Suk Ran Yoon | - |
dc.contributor.author | Soo Yeon Park | - |
dc.contributor.author | Hanna Kim | - |
dc.contributor.author | Sol-Ji Jung | - |
dc.contributor.author | Ye Jin Jang | - |
dc.contributor.author | Min Ho Kang | - |
dc.contributor.author | Young Il Yeom | - |
dc.contributor.author | J L Lee | - |
dc.contributor.author | D Y Kim | - |
dc.contributor.author | Y S Lee | - |
dc.contributor.author | Y A Kang | - |
dc.contributor.author | M Jeon | - |
dc.contributor.author | M Seol | - |
dc.contributor.author | J H Lee | - |
dc.contributor.author | J H Lee | - |
dc.contributor.author | H J Kim | - |
dc.contributor.author | S C Yun | - |
dc.contributor.author | K H Lee | - |
dc.date.accessioned | 2017-04-19T09:52:39Z | - |
dc.date.available | 2017-04-19T09:52:39Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 1083-8791 | - |
dc.identifier.uri | 10.1016/j.bbmt.2014.01.031 | ko |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/11944 | - |
dc.description.abstract | The doses of donor-derived natural killer (NK) cells that can be given safely after human leukocyte antigen (HLA)-haploidentical hematopoietic cell transplantation (HCT) remain to be defined. Forty-one patients (ages 17 to 75years) with hematologic malignancy underwent HLA-haploidentical HCT after reduced-intensity conditioning containing busulfan, fludarabine, and antithymocyte globulin. Cell donors (ages 7 to 62years) underwent growth factor-mobilized leukapheresis for 3 to 4days. Cells collected on the first 2 to 3days were used for HCT, whereas those collected on the last day were CD3-depleted and cultured into NK cells using human interleukins-15 and -21. These NK cells were then infused into patients twice at 2 and 3weeks after HCT at an escalating doses of.2×108cells/kg of body weight (3 patients), 5×108cells/kg (3 patients), 1.0×108cells/kg (8 patients), and ≥ 1.0×108cells/kg or available cells (27 patients). At all dose levels, no acute toxicity was observed after NK cell infusion. After HLA-haploidentical HCT and subsequent donor NK cell infusion, when referenced to 31 historical patients who had undergone HLA-haploidentical HCT after the same conditioning regimen but without high-dose NK cell infusion, there was no significant difference in the cumulative incidences of major HCT outcomes, including engraftment (absolute neutrophil count≥500/μL, 85% versus 87%), grade 2 to 4 acute graft-versus-host disease (GVHD, 17% versus 16%), moderate to severe chronic GVHD (15% versus 10%), and transplantation-related mortality (27% versus 19%). There was, however, a significant reduction in leukemia progression (74% to 46%), with post-transplantation NK cell infusion being an independent predictor for less leukemia progression (hazard ratio, 527). Our findings showed that, when given 2 to 3weeks after HLA-haploidentical HCT, donor-derived NK cells were well tolerated at a median total dose of 2.0×108cells/kg. In addition, they may decrease post-transplantation progression of acute leukemia. | - |
dc.publisher | Elsevier | - |
dc.title | Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study | - |
dc.title.alternative | Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study | - |
dc.type | Article | - |
dc.citation.title | Biology of Blood and Marrow Transplantation | - |
dc.citation.number | 5 | - |
dc.citation.endPage | 704 | - |
dc.citation.startPage | 696 | - |
dc.citation.volume | 20 | - |
dc.contributor.affiliatedAuthor | In Pyo Choi | - |
dc.contributor.affiliatedAuthor | Suk Ran Yoon | - |
dc.contributor.affiliatedAuthor | Soo Yeon Park | - |
dc.contributor.affiliatedAuthor | Hanna Kim | - |
dc.contributor.affiliatedAuthor | Sol-Ji Jung | - |
dc.contributor.affiliatedAuthor | Ye Jin Jang | - |
dc.contributor.affiliatedAuthor | Min Ho Kang | - |
dc.contributor.affiliatedAuthor | Young Il Yeom | - |
dc.contributor.alternativeName | 최인표 | - |
dc.contributor.alternativeName | 윤석란 | - |
dc.contributor.alternativeName | 박수연 | - |
dc.contributor.alternativeName | 김한나 | - |
dc.contributor.alternativeName | 정솔지 | - |
dc.contributor.alternativeName | 장예진 | - |
dc.contributor.alternativeName | 강민호 | - |
dc.contributor.alternativeName | 염영일 | - |
dc.contributor.alternativeName | 이재련 | - |
dc.contributor.alternativeName | 김대영 | - |
dc.contributor.alternativeName | 이영신 | - |
dc.contributor.alternativeName | 강영아 | - |
dc.contributor.alternativeName | 전미진 | - |
dc.contributor.alternativeName | 설미애 | - |
dc.contributor.alternativeName | 이정희 | - |
dc.contributor.alternativeName | 이제환 | - |
dc.contributor.alternativeName | 김화정 | - |
dc.contributor.alternativeName | 윤성철 | - |
dc.contributor.alternativeName | 이규형 | - |
dc.identifier.bibliographicCitation | Biology of Blood and Marrow Transplantation, vol. 20, no. 5, pp. 696-704 | - |
dc.identifier.doi | 10.1016/j.bbmt.2014.01.031 | - |
dc.subject.keyword | Donor natural killer cell infusion | - |
dc.subject.keyword | Human leukocyte antigen-haploidentical hematopoietic cell transplantation | - |
dc.subject.local | Donor natural killer (NK) cell infusion | - |
dc.subject.local | donor NK cell infusion | - |
dc.subject.local | Donor natural killer cell infusion | - |
dc.subject.local | Human leukocyte antigen-haploidentical hematopoietic cell transplantation | - |
dc.description.journalClass | Y | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.